DE1467832A1 - Pharmazeutische Praeparate - Google Patents

Pharmazeutische Praeparate

Info

Publication number
DE1467832A1
DE1467832A1 DE19641467832 DE1467832A DE1467832A1 DE 1467832 A1 DE1467832 A1 DE 1467832A1 DE 19641467832 DE19641467832 DE 19641467832 DE 1467832 A DE1467832 A DE 1467832A DE 1467832 A1 DE1467832 A1 DE 1467832A1
Authority
DE
Germany
Prior art keywords
pharmaceutical preparations
phenyl
sulfonamide
formula
preparations according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
DE19641467832
Other languages
German (de)
English (en)
Inventor
Christensen Dr Lauri Korsgaard
Schmidt Dr Paul
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Ciba Geigy AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy AG filed Critical Ciba Geigy AG
Publication of DE1467832A1 publication Critical patent/DE1467832A1/de
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38Nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/63Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/64Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38Nitrogen atoms
    • C07D231/42Benzene-sulfonamido pyrazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/44Oxygen and nitrogen or sulfur and nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE19641467832 1963-11-05 1964-11-02 Pharmazeutische Praeparate Pending DE1467832A1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH1359863 1963-11-05
CH1210364 1964-09-17

Publications (1)

Publication Number Publication Date
DE1467832A1 true DE1467832A1 (de) 1968-11-28

Family

ID=25709624

Family Applications (1)

Application Number Title Priority Date Filing Date
DE19641467832 Pending DE1467832A1 (de) 1963-11-05 1964-11-02 Pharmazeutische Praeparate

Country Status (5)

Country Link
BE (1) BE655242A (enExample)
DE (1) DE1467832A1 (enExample)
FR (2) FR3797M (enExample)
GB (1) GB1054278A (enExample)
NL (1) NL6412822A (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0192951A3 (de) * 1985-02-02 1986-09-10 Bayer Ag 5-Sulfonamido-1-aryl-pyrazole

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013046041A1 (en) 2011-09-30 2013-04-04 Synovo Gmbh Pyridinylpyrazoles for use as kinase modulators for the treatment of cancer
JP6263553B2 (ja) 2013-01-17 2018-01-17 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft Cns疾患の処置のためのオキシトシン受容体アゴニスト
RU2579515C1 (ru) * 2014-12-29 2016-04-10 Федеральное государственное бюджетное образовательное учреждение высшего образования "Сибирский государственный технологический университет" (СибГТУ) Алкоксиметилзамещенные 1н-4-аминопиразолы

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0192951A3 (de) * 1985-02-02 1986-09-10 Bayer Ag 5-Sulfonamido-1-aryl-pyrazole
US4806144A (en) * 1985-02-02 1989-02-21 Bayer Aktiengesellschaft 5-Sulphonamido-1-aryl-pyrazoles

Also Published As

Publication number Publication date
GB1054278A (en) 1967-01-11
FR3797M (fr) 1965-12-27
FR4034M (enExample) 1966-03-28
NL6412822A (enExample) 1965-05-06
BE655242A (enExample) 1965-05-04

Similar Documents

Publication Publication Date Title
EP0527736B1 (de) Isoxazol-4-carbonsäureamide und hydroxyalkyliden-cyanessigsäureamide, diese verbindungen enthaltende arzneimittel und deren verwendung
DE1770447A1 (de) In 1-Stellung substituierte 1,4-Dihydro-6,7-methylendioxy-4-oxo-chinolin-3-carbonsaeure-Derivate
CH616923A5 (enExample)
CH635586A5 (de) Verfahren zur herstellung von 1,3-dihydroimidazo(4,5-b)pyridin-2-onen.
DE3231255A1 (de) Tetrazin-derivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen
DE2408906A1 (de) 6-styrylpyrazolo(3,4-d)pyrimidin-4-one und -pyrimidine mit ihren salzen
EP0041215A2 (de) Imidazoazolalkensäureamide, neue Zwischenprodukte zu ihrer Herstellung, ihre Herstellung und ihre Verwendung in Arzneimitteln
DE2012138A1 (de) Neue Pyrazinderivate und diese enthaltende pharmazeutische Präparate
EP0202673B1 (de) Cytostatisch wirksame Titanocen-Komplexe
DE69002384T2 (de) Heterocyclische Guanidine als 5HT-3-Antagonisten.
DE2405395A1 (de) Verfahren zur herstellung von neuen azinen und ihren tautomeren
DE1467832A1 (de) Pharmazeutische Praeparate
DE2114629A1 (de) Heterocyclische Acylaminoäthylbenzolsulfonylharnstoffe
DE2427272C3 (de) 1-(2-(β-Naphthyloxy)-äthyl)-3-methyl -pyrazolon-(5), Verfahren sowie Verwendung als Antithrombotikum
EP0088323B1 (de) Imidazothiadiazolalkencarbonsäureamide, neue Zwischenprodukte zu ihrer Herstellung, ihre Herstellung und ihre Verwendung in Arzneimitteln
DE2804909A1 (de) Imidazo eckige klammer auf 1,5-b eckige klammer zu -pyridazine
DE2208368C3 (de) 1 -Phenyl-S-hydroxy-S-methyltriazene und Verfahren zu ihrer Herstellung
DE1445579A1 (de) Neue Aminopyrazole
DE1695532A1 (de) Chinoxalinverbindungen sowie Verfahren zu deren Herstellung
DE2053205A1 (de) Dihydrofurandenvate und Verfahren zu deren Herstellung
DE2319281A1 (de) Diuretisches und antihypertensives mittel
EP0158083A2 (de) Arzneimittel
DE2423725A1 (de) 5-phenyl-4-oxo-delta hoch 2,alphathiazolidinessigsaeureester
AT362386B (de) Verfahren zur herstellung von neuen guanidin- derivaten und von deren saeureadditionssalzen
DE2230792A1 (de) 3-amino-pyrazolone-(5), verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel